Back to search

Article

Impact of PCSK9 inhibitors on bone disease: A comprehensive drug-target Mendelian randomization study

2025-03-11

Abstract excerpt

<h4>Background</h4> While certain studies suggest a relationship between hyperlipidemia and bone metabolism, the exact nature of proprotein convertase subtilisin/kexin 9 inhibitors (PCSK9i, targeted by, eg, alirocumab), which were originally developed for lowering LDL cholesterol inhibitors, with bone disease is still unclear. This research endeavors to uncover the potential causal relationship between PCSK9i and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ef90027b-7c32-5311-96de-ad7d6aa1a35a
DOI
10.1101/2025.03.09.25323603
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Impact of PCSK9 inhibitors on bone disease: A comprehensive drug-target Mendelian randomization studyDOI 10.1101/2025.03.09.25323603
Select a neighboring publication to make it the new centre.